C8 MediSensors Gains CE Mark Approval for the C8 MediSensors Optical Glucose Monitor(TM) System for People with Diabetes

C8 MediSensors Gains CE Mark Approval for the C8 MediSensors Optical Glucose Monitor(TM) System for People with Diabetes PR Newswire SAN JOSE, California, October 25, 2012 SAN JOSE, California, October 25, 2012 /PRNewswire/ -- A new non-invasive continuous glucose monitor is approved for marketing in Europe C8 MediSensors, Inc. (http://www.c8medisensors.com) has today announced it received CE Mark approval for its Optical Glucose Monitor System, allowing the device, a new non-invasive continuous glucose monitor (nCGM), to be marketed in Europe. http://www.c8medisensors.com The comprehensive, 10-year Diabetes Control and Complications Trial (DCCT) clearly demonstrated that individuals with type 1 diabetes who kept blood glucose levels as close to normal as possible for as long as possible had less chance of developing disease-related complications. The DCCT found that the risk of eye disease was reduced by [1]76%, kidney disease by 50% and nerve disease by 60%. Since that time, other studies have confirmed the importance of tight glycaemic control with minimal glucose excursions in reducing disease-related complications not [2-6]only in type 1 diabetes, but also in type 2. In addition, a large number of studies have shown that continuous glucose [7-19]monitors (CGM) can improve glycaemic control with reduced risk of hypoglycaemia. CGMs are adjunct devices that are intended to complement finger stick blood glucose tests.